iShares Core Dividend ETF (DIVB)
Live price chart, market sentiment, and community perspectives for iShares Core Dividend ETF (CBOE: DIVB).
Live price chart, market sentiment, and community perspectives for iShares Core Dividend ETF (CBOE: DIVB).
On our desk, we are seeing increasing client rotation out of mega-cap tech and into DIVB as an effective AI-hedging wave play. The fund's unique exclusion of the Magnificent 7 combined with its emphasis on a 75% dividend and 25% buyback yield structure has created a compelling narrative for total shareholder return that traditional income funds simply cannot match.
Looking at the quantitative risk metrics, DIVB presents a fascinating paradox. While its 3-year Sharpe ratio of 1.17 outpaces the Large Value category median of 0.91, its portfolio risk score sits at 70 (Aggressive). The 5-year maximum drawdown of -19.9% and standard deviation of 15.2% indicate that the fund absorbs more downside volatility than typical conservative peers.
Watching the macro transition with the Fed holding rates in the 4.25%-4.50% range, dividend-and-buyback strategies are gaining traction. However, trade-policy uncertainty remains a near-term drag. Even though DIVB trades +2.77% above its 200-day moving average of 52.73 with a neutral RSI of 49.7, its starting yield of around 2% requires patient, buy-and-hold capital rather than tactical income seekers.
In our risk management review, we noted that DIVB's 5-year downside capture of 89 underperforms the category average of 83, meaning it takes on more downward momentum during market corrections. Investors must weigh this against its impressive 3-year and 5-year compounding capabilities and its ability to outpace standard market benchmarks during periods of sector rotation.
From a portfolio construction standpoint, the December 2022 strategy overhaul fundamentally changed DIVB's positioning by aligning it more closely with the broader equity market while prioritizing dividends over buybacks. With a low expense ratio of 0.05% and a portfolio-level P/E of 13.05, it provides a very attractive valuation cushion against cooling macroeconomic indicators like the ISM Manufacturing PMI at 48.5.
Explore plasma cleansing, somatic organ swaps, and BCI.